Stock Events

Stock Events

Search...

Biocure Technology

€0

0

+€0+0% Thursday 06:02

Statistics

Day High

0

Day Low

0

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

960,835

P/E Ratio

0.03

Dividend Yield

-

Dividend

-

Earnings

30SepConfirmed

Q4 2019

Q1 2020

Q2 2020

Q3 2020

Q4 2020

Q1 2021

Q2 2021

-0.01

-0.01

-0

0

Expected EPS

N/A

Actual EPS

-0.0103

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1WH.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a major player in the biopharmaceutical sector, directly competing in the development and commercialization of medical therapies, similar to Biocure Technology's focus.

Merck operates in the pharmaceutical industry, developing drugs that could potentially compete with Biocure's product offerings in various therapeutic areas.

Gilead Sciences

Gilead Sciences is involved in the research and development of innovative therapeutics, closely aligning with Biocure's mission in the biotech field.

Amgen focuses on human therapeutics, a field directly relevant to Biocure's work in biopharmaceuticals, making them a direct competitor.

Biogen's emphasis on advanced biologics and therapies for neurological diseases places it in direct competition with Biocure's therapeutic developments.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals specializes in the invention of medicines for serious medical conditions, competing in the same innovative biopharmaceutical space as Biocure.

Vertex Pharmaceuticals

Vertex Pharmaceuticals concentrates on creating new treatments for life-threatening diseases, which overlaps with Biocure's focus areas.

Novartis is a global healthcare company that develops treatments across a broad range of areas, potentially competing with Biocure's products and research.

AstraZeneca engages in the development of pharmaceutical products, including areas that may overlap with Biocure's therapeutic targets.

About

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

Show more...

CEO

Dr. Björn Cochlovius Ph.D.

Country

CA

ISIN

CA09075T1075

WKN

000A2JGTL

Listings